文献速递前列腺癌

评估根治性前列腺切除术后挽救性放疗联合激素治疗的作用与最佳疗程:一项多中心研究结果

Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study.
PubMed 文献 · Eur Urol · 2019-02-22

该多中心研究纳入1264例根治性前列腺切除术后接受挽救性放疗的患者,中位激素治疗疗程9个月。多变量分析显示激素治疗疗程与临床复发风险呈负相关(HR 0.95,p=0.022)。激素治疗疗程与临床复发的关联因风险因素数量而异:≥2个风险因素者长疗程(至36个月)获益显著,1个风险因素者短疗程(<12个月)略有获益,无风险因素者未见显著获益。

要点

  • 挽救性放疗联合激素治疗疗程与临床复发风险呈负相关(HR 0.95,p=0.022)。
  • ≥2个风险因素者激素治疗至36个月有显著获益。
  • 1个风险因素者短疗程(<12个月)略有获益;无风险因素者无显著获益。

核心结论

  • 根治性前列腺切除术后因PSA升高接受挽救性放疗的患者,激素治疗疗程的肿瘤学获益取决于其临床和病理特征。
  • 数据提示≥2个不良特征的患者长疗程激素治疗有显著效应;单个风险因素者短疗程足够;无任何风险因素者联合激素治疗未见显著获益。

研究设计与样本

  • 多中心研究,纳入8家转诊中心根治性前列腺切除术后接受前列腺及精囊床挽救性放疗的1264例患者。
  • 挽救性放疗指征为PSA升高或术后PSA持续(术后1个月PSA ≥0.1 ng/ml);同期激素治疗由主治医师决定。
  • 采用多变量Cox回归分析激素治疗疗程与临床复发的关联,并进行交互检验;预设三个风险因素:pT分期≥pT3b、病理Gleason≥8、挽救性放疗时PSA>0.5 ng/ml。

主要发现

  • 1125例(89%)因PSA升高接受挽救性放疗,139例(11%)因PSA持续接受治疗;363例(29%)接受同期激素治疗,中位疗程9个月。
  • 术后中位随访93个月,182例出现临床复发;8年无临床复发生存率为92%。
  • 多变量分析中,激素治疗疗程与临床复发风险呈负相关(HR 0.95;p=0.022)。
  • 531例(42%)无预设风险因素,507例(40%)有1个,226例(18%)有≥2个;激素治疗疗程与临床复发的关联因风险因素数量显著不同(0 vs 1,p=0.001;0 vs ≥2,p<0.0001)。
  • ≥2个风险因素者激素治疗至36个月有显著获益;1个风险因素者短疗程(<12个月)略有获益;无风险因素者临床复发风险低且恒定,与激素治疗疗程无关。

临床怎么用

  • 作者认为,≥2个不良特征的患者可从长疗程同期激素治疗中获益。
  • 作者认为,单个风险因素者短疗程激素治疗可能合理。
  • 无任何风险因素者联合激素治疗未显示显著获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal duration of hormonal therapy (HT) when associated with postprostatectomy radiation therapy (RT) remains controversial. OBJECTIVE: To test the impact of HT duration among patients treated with postprostatectomy RT, stratified by clinical and pathologic characteristics. DESIGN, SETTING, AND PARTICIPANTS: The study included 1264 patients who received salvage RT (SRT) to the prostatic and seminal vesicle bed at eight referral centers after radical prostatectomy (RP). Patients received SRT for either rising prostate-specific antigen (PSA) or PSA persistence after RP, defined as PSA ≥0.1ng/ml at 1mo after surgery. Administration of concomitant HT was at the discretion of the treating physician. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome of interest was clinical recurrence (CR) after SRT, as identified by imaging. Multivariable Cox regression analysis was used to test the association between CR and HT duration. We applied an interaction test between HT duration and baseline risk factors to assess the hypothesis that CR-free survival differed by HT duration according to patient profile. Three risk factors were prespecified for evaluation: pT stage ≥pT3b, pathologic Gleason ≥8, and PSA level at SRT >0.5 ng/ml. The relationship between HT duration and CR-free survival rate at 8yr was graphically explored according to the number of risk factors (0 vs 1 vs ≥2). RESULTS AND LIMITATIONS: Overall, 1125 men (89%) received SRT for rising PSA and 139 (11%) were treated for PSA persistence. Concomitant HT was administered to 363 patients (29%), with a median HT duration of 9mo. At median follow-up of 93mo after surgery, 182 patients developed CR. The 8-yr CR-free survival was 92%. On multivariable analysis, HT duration was inversely associated with the risk of CR (hazard ratio 0.95; p=0.022). A total of 531 (42%) patients had none of the prespecified risk factors, while 507 (40%) had one and 226 (18%) had two or more risk factors. The association between HT duration and CR was significantly different by risk factors (0 vs 1, p=0.001; 0 vs ≥2, p<0.0001). We observed a significant effect of HT duration for patients with two or more risk factors, for whom HT administration was beneficial when given for up to 36mo. This effect was attenuated among patients with one risk factor, with concomitant HT slightly beneficial when administered for a shorter time (<12mo). Conversely, for patients with no risk factors, the risk of CR remained low and constant regardless of HT duration. CONCLUSIONS: The oncologic benefit of HT duration among men receiving SRT for increasing PSA after RP depends on their clinical and pathologic characteristics. Our data suggested a significant effect of long-term HT for patients with two or more adverse features. Conversely, short-term HT was sufficient for patients with a single risk factor, whereas patients without any risk factors did not show a significant benefit from concomitant HT. PATIENT SUMMARY: We tested the impact of hormonal therapy (HT) duration during radiation therapy after radical prostatectomy. We identified three risk factors and observed a different impact of HT duration by clinical and pathologic characteristics. Patients with more adverse features benefit from long-term concomitant HT. On the contrary, for patients with a single risk factor, short-term HT may be reasonable. Patients without any risk factors did not show a significant benefit from concomitant HT.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Fossati N, Robesti D, Karnes RJ, et al. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. Eur Urol. 2019. PMID: 30799187. doi:10.1016/j.eururo.2019.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。